Skip to main content
SpringerLink
Log in

Retroperitoneal lymph node dissection for high-risk stage I and stage IIA seminoma

  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Introduction:

The clinical results of radiotherapy in low-stage seminoma are excellent with negligible early morbidity. However, in a long-term follow-up various complications may occur. On the other hand, experience in nonseminomas shows that surgical morbidity has decreased markedly after invention of a nerve-sparing technique. These issues served as a rationale for us to perform the primary retroperitoneal lymph node dissection (RPLND) in seminoma patients.

Materials and methods:

Fourteen pure seminoma patients (10 high-risk stage I and four with clinical stage IIA) underwent nerve-sparing RPLND from September, 1997 to December, 2002.

Results:

Pathological evaluation revealed lymph node involvement in three out of 10 clinical stage I and in all four stage IIA cases. The patients’ acceptance of the surgery was good. Minor intra- and early postoperative complications were observed in two cases. Antegrade ejaculation was preserved in all patients. No retroperitoneal or distant recurrences have been observed. All patients were free of disease with the mean follow-up period of 56 months.

Conclusion:

The excellent results and minimum morbidity of nerve-sparing RPLND together with the increased concerns on late complications of radiotherapy may turn the preference of surgery in low-stage seminoma into the subject of future discussion.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Specht L and Jacobsen GK (1993). Surveillance following orchidectomy for stage I seminoma of the testis. Eur J Cancer 29A(14): 1931–1934

    Article  PubMed  Google Scholar 

  2. Warde P and Jewett MAS (1998). Surveillance for stage I testicular seminoma. Is it a good option?. Urol Clin North Am 25(3): 425–433

    Article  PubMed  CAS  Google Scholar 

  3. Oliver RTD, Edmonds PM and Ong JYH (1994). Pilot studies of 2 and 1 course carboplatin as adjuvant for stage I seminoma: should it be tested in a randomized trial against radiotherapy?. Int J Radiat Oncol Biol Phys 29(1): 3–8

    PubMed  CAS  Google Scholar 

  4. Dieckmann KP, Krain J, Kuster J and Bruggeboes B (1996). Adjuvant carboplatin treatment for seminoma clinical stage I. J Cancer Res Clin Oncol 122(1): 63–66

    Article  PubMed  CAS  Google Scholar 

  5. Warde P, Specht L and Horwich A (2002). Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol 20(22): 4448–4452

    Article  PubMed  Google Scholar 

  6. Laguna MP, Pizzocaro G and Klepp O (2001). EAU guidelines on testicular cancer. Eur Urol 40(2): 102–110

    Article  PubMed  CAS  Google Scholar 

  7. Krege S, Souchon R and Schmoll HJ (2001). Interdisciplinary consensus on diagnosis and treatment of testicular germ cell tumors: result of an update conference on evidence-based medicine (EBM). Eur Urol 40(4): 372–391

    Article  PubMed  CAS  Google Scholar 

  8. Jewett MAS, Kong YSP and Goldberg SD (1988). Retroperitoneal lymphadenectomy for testis tumor with nerve-sparing for ejaculation. J Urol 139(6): 1220–1224

    PubMed  CAS  Google Scholar 

  9. Weissbach L and Boedefeld EA (1990). Surgical treatment of stage-I non-seminomatous germ cell testis tumor. Eur Urol 17(2): 97–106

    PubMed  CAS  Google Scholar 

  10. Donohue JP, Foster RS and Rowland RG (1990). Nerve-sparing retroperitoneal lymphadenectomy with preservation of ejaculation. J Urol 144(2 Pt 1): 287–291

    PubMed  CAS  Google Scholar 

  11. Richie JP (1990). Clinical stage 1 testicular cancer: the role of modified retroperitoneal lymphadenectomy. J Urol 144(5): 1160–1163

    PubMed  CAS  Google Scholar 

  12. Baniel J, Foster RS and Rowland RG (1994). Complications of primary retroperitoneal lymph node dissection. J Urol 152(2 Pt 1): 424–427

    PubMed  CAS  Google Scholar 

  13. Heidenreich A, Albers P and Hartmann M (2003). Complications of primary nerve sparing retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumors of the testis: experience of the German Testicular Cancer Study Group. J Urol 169(5): 1710–1714

    Article  PubMed  Google Scholar 

  14. Albers P, Foster RS, Donohue JP and Voges GE (1997). Retroperitoneal lymph node dissection (RPLND): a nerve-sparing operative approach. In: Hohenfellner, R, Novick, A, and Fichtner, J (eds) Innovations in Urologic Surgery, pp 577–585. Isis Medical Media, Oxford

    Google Scholar 

  15. Hanks GE, Peters T and Owen J (1992). Seminoma of the testis: long-term beneficial and deleterious results of radiation. Int J Radiat Oncol Biol Phis 24(5): 913–919

    Article  CAS  Google Scholar 

  16. Bokemeyer C and Schmoll HJ (1993). Secondary neoplasms following treatment of malignant germ cell tumors. J Clin Oncol 11(9): 1703–1709

    PubMed  CAS  Google Scholar 

  17. Stiggelbout AM (1993). Second cancer risk following testicular cancer: a follow-up study of 1909 patients. J Clin Oncol 11(3): 415–424

    PubMed  Google Scholar 

  18. Moller H, Mellemgaard A and Jacobsen GK (1993). Incidence of second primary cancer following testicular cancer. Eur J Cancer 29A(5): 672–676

    Article  PubMed  CAS  Google Scholar 

  19. Wanderas EH, Fossa SD and Tretli S (1997). Risk of subsequent non-germ cell cancer after treatment of germ cell cancer in 2006 Norwegian male patients. Eur J Cancer 33(2): 253–262

    Article  PubMed  CAS  Google Scholar 

  20. Travis LB, Curtis RE and Storm H (1997). Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst 89(19): 1429–1439

    Article  PubMed  CAS  Google Scholar 

  21. Ruther U, Dieckmann K and Bussar-Maatz R (2000). Second malignancies following pure seminoma. Oncology 58(1): 75–82

    Article  PubMed  CAS  Google Scholar 

  22. Huddart RA, Norman A and Shahidi M (2003). Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 21(8): 1513–1523

    Article  PubMed  CAS  Google Scholar 

  23. Hamilton CR, Horwich A, Bliss JM and Peckham MJ (1987). Gastrointestinal morbidity of adjuvant radiotherapy in stage I malignant teratoma of the testis. Radiother Oncol 10(2): 85–90

    PubMed  CAS  Google Scholar 

  24. Aass N, Fossa SD, Theodorsen L and Norman N (1991). Prediction of long-term gonadal toxicity after standard treatment for testicular cancer. Eur J Cancer 27(9): 1087–1091

    Article  PubMed  CAS  Google Scholar 

  25. Schover LR and Gonzales M (1986). Sexual and marital relationships after radiotherapy for seminoma. Urology 27(2): 117–123

    Article  PubMed  CAS  Google Scholar 

  26. Stein M, Steiner M and Moshkowitz B (1994). Testicular seminoma: 20-year experience at the Northern Israel Oncology Center (1968–1988). Int Urol Nephrol 26(4): 461–469

    PubMed  CAS  Google Scholar 

  27. Zagars GK, Ballo MT, Lee AK and Strom SS (2004). Mortality after cure of testicular seminoma. J Clin Oncol 22(4): 640–647

    Article  PubMed  Google Scholar 

  28. Fossa SD, Horwich A and Russell JM (1999). Optimal planning target volume for stage I testicular seminoma: a medical research council randomized trial. J Clin Oncol 17(4): 1146–1154

    PubMed  CAS  Google Scholar 

  29. Jones WG, Fossa SD and Mead GM (2002). A randomized trial of two radiotherapy schedules in the adjuvant treatment of stage I seminoma (MRC TE18) – preliminary report. In: Harnden, P, Joffe, JK, and Jones, WG (eds) Germ Cell Tumours V, pp 235–236. Springer-Verlag, London

    Google Scholar 

  30. Horwich A (2004). Radiotherapy in stage I seminoma of the testis (editorial). J Clin Oncol 22(4): 585–588

    Article  PubMed  Google Scholar 

  31. Warszawski N and Schmucking M (1997). Relapses in early-stage testicular seminoma: radiation therapy versus retroperitoneal lymphadenectomy. Scand J Urol Nephrol 31(4): 355–359

    PubMed  CAS  Google Scholar 

  32. Sharir S, Foster RS, Donohue JP and Jewett MAS (1996). What is the appropriate follow-up after treatment?. Semin Urol Oncol 14(1): 45–53

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. National Center of Urology, Tsinandali Str. 9, 0144, Tbilisi, Georgia, USA

    Zaza Mezvrishvili & Laurent Managadze

Authors
  1. Zaza Mezvrishvili
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Laurent Managadze
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zaza Mezvrishvili.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mezvrishvili, Z., Managadze, L. Retroperitoneal lymph node dissection for high-risk stage I and stage IIA seminoma. Int Urol Nephrol 38, 615–619 (2006). https://doi.org/10.1007/s11255-005-4793-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-005-4793-x

Keywords

Search

Navigation